Dacarbazine (DTIC)
General information
Class/mechanism: Alkylator, purine analog, inhibits DNA synthesis; exact mechanism unclear. Converted to the active alkylating metabolite MTIC.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is established (work in progress)
Diseases for which it is used
Patient drug information
- Dacarbazine (DTIC) patient drug information (Chemocare)[3]
- Dacarbazine (DTIC) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1975-05-27: Initial FDA approval
- Uncertain date: indicated in the treatment of metastatic malignant melanoma. (No supporting studies are cited)
- Uncertain date: Indicated for Hodgkin's disease as a second-line therapy when used in combination with other effective agents. (No supporting studies are cited)
Also known as
- Generic names: dacarbazin, DTIC, imidazole carboxamide
- Brand names: Bazipar, Cedcozine, Dacarba, Dacarex, Dacin, Dacmed, Darbazine, Dazine, Decarb, Oncodac, Zydac
References
Categories:
- Drugs
- Intravenous medications
- Irritant
- Alkylating agents
- Triazenes
- Human DNA synthesis inhibitors
- Antimetabolites
- Purine analogues
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Leiomyosarcoma medications
- Liposarcoma medications
- Melanoma medications
- Neuroblastoma medications
- Pheochromocytoma medications
- Soft tissue sarcoma medications
- Uveal melanoma medications
- FDA approved in 1975
- WHO Essential Cancer Medicine